Archives des Unclassified - delbertpharma.com

Delbert Pharma announces the acquisition of Azactam® (aztreonam) from Bristol Myers Squibb

Dec 18, 2024 | Unclassified

Paris, December 13, 2024 – Delbert Pharma, a French pharmaceutical company dedicated to safeguarding essential medicines, announces the acquisition of the injectable aztreonam (Azactam®) molecule from Bristol Myers Squibb.

This acquisition represents a major milestone in the history of Delbert Pharma, expanding its international presence beyond Europe in the field of infectious diseases.
This acquisition includes the Marketing Authorizations (MAs), as well as the trademark, of the injectable forms of this antibiotic Azactam ®1g and Azactam® 2g in nearly 20 countries worldwide where it is marketed.
The transfer of the Marketing Authorizations will occur progressively across the different countries throughout 2025, and Bristol Myers Squibb or their local partners will remain the holders of these MAs during this transition period.

With its expertise in relocating production, Delbert Pharma will also lead the industrial transfer for the production of Azactam® and will make every effort to ensure the continuity and availability of the product for patients globally.

“This acquisition represents a significant step in our growth strategy. By adding Azactam® to our portfolio of injectable antibiotics, we strengthen our commitment to providing international access to essential treatments. This is a new chapter for Delbert Pharma, demonstrating our determination to expand our presence beyond Europe and to continue meeting essential medical needs worldwide, ” stated Eric Fidelin, Executive General Director of Delbert Pharma.

Ensuring the maintenance and development of medications whose absence could be detrimental to patients and to the balance of the healthcare systems is our core mission. The acquisition of Azactam® further strengthens Delbert Pharma’s commitment as a mission-driven company.

We thank Bristol Myers Squibb for the mutual trust shared over many years between our two companies, as Azactam is the fourth Bristol Myers Squibb product acquired by Delbert Pharma in the past decade.

About Delbert Pharma

Delbert Pharma is an independent French pharmaceutical company founded in 2013 and a mission-driven company since 2023, dedicated to preserving essential medicines for the stability of healthcare systems. Delbert Pharma offers a broad range of treatments in infectious diseases, neurology, and onco-hematology, addressing critical medical needs in Europe and beyond. The company is strongly committed to combating medicine shortages and fostering pharmaceutical reindustrialization.

About Azactam

Aztreonam (Azactam®) is an injectable antibiotic of the monobactam class, primarily used to treat severe infections caused by Gram-negative bacteria, including septicemia, urinary tract infections, skin and soft tissue infections, bronchopulmonary, intra-abdominal, and gyneco-obstetric infections. As a key therapeutic agent, Azactam® is particularly valuable given the rise in infections resistant to beta-lactam antibiotics, making the availability of alternative treatments essential..

Delbert Pharma awarded Mission-driven company status

Sep 27, 2023 | Unclassified

Paris, 09/27/2023

Delbert Pharma, a major player in the safeguarding and relocation of essential medicines, is proud to announce that it has officially been awarded Mission-driven company status in September 2023.

This recognition, the fruit of intense collaborative work and a deep commitment to patients, is in line with the company’s core values: guaranteeing access to treatments critical to public health. Since its creation in 2002, Delbert Pharma has distinguished itself by its primary mission: to prevent the disappearance of essential medicines deemed insufficiently profitable by the pharmaceutical industry. This ambition, rooted in the company’s ethical values, aims to combat the loss of opportunity for patients by ensuring the availability of drugs of major therapeutic interest.

A mission for the common good

The Mission-driven company status, introduced by the 2019 PACTE law, enables companies to formalize their commitment to social and environmental objectives, while continuing their economic activity. At Delbert Pharma, this approach is reflected in precise statutory objectives, integrated into the company’s articles of association, aimed at:
– Maintaining and developing medicines whose absence would harm patients and the balance of healthcare systems.
– Relocating production to Europe to preserve exceptional know-how while reducing the ecological footprint.
– Offering a working ecosystem that promotes the well-being of employees and partners.

A collective commitment to public health.

Obtaining this status marks a turning point in the history of Delbert Pharma, uniting all our teams and partners around our mission. “We have always placed patients’ interests at the heart of our actions, by guaranteeing access to treatments without alternatives. This status is official recognition of our efforts, and commits us to continuing along this path,” explains Thierry Hoffmann, co-founder of Delbert Pharma.

Next steps

With an ambitious roadmap, Delbert Pharma is committed to publishing an annual mission report, overseen by a mission committee made up of internal and external stakeholders. The report will track progress in the areas of public health, quality of working life and environmental responsibility.
Delbert Pharma is one of only two mission-driven pharmaceutical companies in France, illustrating its determination to combine economic performance with social utility.
” This approach, supported by our raison d’être and our statutory objectives, involves all our teams, federates them, and makes the company shine beyond our walls” mentions Eric Fidelin, Executive General Manager of Delbert Pharma. For further information, please contact: Delbert Pharma
Telephone: 01 46 99 68 20
E-mail: contact@delbert.fr
Website: www.delbertpharma.com

New investment in Laboratoires Delbert

Apr 24, 2023 | Unclassified

PRESS RELEASE - April 24, 2023

Vivalto Partners announces a significant investment in Laboratoires Delbert to support the company’s development in the field of essential and orphan drugs. The historical investors – Sagard NewGen, Socadif Capital Investissement, IDIA Capital Investissement and MACSF – are also reinvesting in the transaction.

Vivalto Partners, a management company set up in 2021 by Daniel Caille, founder of the Vivalto Santé group of clinics, announces the closing of a significant investment in Laboratoires Delbert alongside its two founders Marc Childs and Thierry Hoffmann, their management team and all the financial investors who acquired a stake in the company in 2020 (Sagard NewGen, Socadif Capital Investissement, IDIA Capital Investissement and MACSF). This investment will enable Laboratoires Delbert to enter a new phase of development, giving them the means to support the strong growth of their business, and to contribute to meeting drug shortages.

Acquired in 2013 and since managed by Marc Childs and Thierry Hoffmann, Laboratoires Delbert specializes in acquiring and maintaining on the market drugs of major therapeutic interest or essential as defined by the World Health Organization. Active in three major therapeutic areas (infectiology, central nervous system and oncology), Laboratoires Delbert has recognized expertise in securing the production chain, enabling it to limit the risks of supply disruptions and position itself as a benchmark partner for regulatory authorities and major pharmaceutical groups alike. These skills have also enabled the company to expand into orphan diseases by repositioning molecules already on the market.

Drawing on its expertise and network in the healthcare sector, Vivalto Partners intends to support Laboratoires Delbert in a new stage of its development, enabling it to strengthen its position, particularly internationally and in new therapeutic indications. What’s more, like Vivalto Santé, Laboratoires Delbert has made the ambitious decision to obtain Entreprise à Mission status in the near future.

Marc Childs and Thierry Hoffmann, said: “We are delighted to welcome Vivalto Partners, a new financial partner specialized in the healthcare sector and endowed with a genuine entrepreneurial spirit. With the management team and our long-standing shareholders (Sagard NewGen, Socadif Capital Investissement, IDIA Capital Investissement and MACSF) continuing the adventure we embarked upon three years ago, we will be able to reach a new milestone and continue to cultivate our vocation: to maintain access for patients to certain essential medicines neglected by the market, and to revive and enrich pharmaceutical specialties for the benefit of as many people as possible”.

Daniel Caille, Chairman of Vivalto Partners, adds: “ We are sincerely delighted to support Marc and Thierry and their formidable team in the development of their product portfolio in France and abroad. Laboratoires Delbert has demonstrated its indispensable role in keeping vital drugs on the market for the treatment of numerous pathologies. This is perfectly in line with the values we wish to uphold by investing in healthcare: caring for life. . »

Participants in the operation :

Laboratoires Delbert: Marc Childs, Thierry Hoffmann, Eric Fidelin, Rohald Meyer
Vivalto Partners: Daniel Caille, Sébastien Alauzet, Charles-Eric François, Georges Weill
Sagard NewGen: Bérangère Barbe, Agnès Huyghues Despointes, Louis Gosselin
Socadif Capital Investissement: Thierry Antonini, Emmanuel David
IDIA Capital Investissement: Nicolas Lambert, Jean Lebreton, Faora Narayanan
MACSF: Roger Caniard
Board of Directors : Edmond de Rothschild (Arnaud Petit, Anastasia Saldi, Augustin Hay, Tristan Gonnord, Paul Assaël, Arnaud Jolly, Thibault Blanc) – Neuflize OBC (Jean-Christophe Liard) – LPA (Raphaël Chantelot, Maxime Ponsan, Mathieu Selva-Roudon, Céline Guo) – Roland Berger (Frédéric Thomas) – KPMG (Antoine Bernabeu)
Vivalto Partners advisors: Fieldfisher (Pascal Squercioni, Natalia Toribio, Lorette Cassard) – CMS (Arnaud Hugot, Antoine Melchior) – Cepton (Matthias Bucher) – Alvarez & Marsal (Frédéric Steiner, Guillaume Descamps)
Financing banks: Caisse Régionale de Crédit Agricole Mutuel de Paris et d’Ile de France (Issam El Fehham, Gregory Leguet, Nicolas Bouchet), Crédit Agricole Corporate and Investment Bank, Artemid, Société Générale, Banque Populaire Rives de Paris, Neuflize OBC
PIK : Bpifrance Investissement, CIC Private Debt

About Laboratoires Delbert

Laboratoires Delbert’s mission is to maintain access to medicines of major therapeutic interest (MITM) for patients. Every year, Laboratoires Delbert acquires new drugs whose future is in jeopardy. Laboratoires Delbert is concentrating its efforts on finding production sites in Europe. With the help of its staff and the support of clinicians, galenicists, engineers and chemists, Laboratoires Delbert brings these drugs back to life, to guarantee their availability to the medical profession and to patients. Laboratoires Delbert achieved sales of almost €35 million in 2022.

About Vivalto Partners

Founded in 2021 in Paris by Daniel Caille, Vivalto Partners is a management company approved by the Autorité des Marchés Financiers (AMF). The team supports profitable European companies that contribute to the quality of healthcare. The fund has a strong ESG focus, as well as a responsible approach to value creation. The management company is a member of the France Invest association, and will be a signatory of the United Nations Principles for Responsible Investment.
For further information, www.vivaltopartners.com

Laboratoires Delbert signs the Supplier Relations and Purchasing Charter

Jan 23, 2023 | Unclassified

Laboratoires Delbert is pleased to announce that it has signed the Responsible Purchasing and Supplier Relations (RFAR) charter.

Committed since its creation to responsible approaches with its suppliers, on January 23, 2023 Laboratoires Delbert formalized these commitments by becoming a signatory to the “Responsible Supplier Relations and Purchasing” Charter steered by the Médiateur des Entreprises and the CNA (Conseil National des Achats).

This approach is part of Laboratoires Delbert’s ongoing efforts to integrate environmental and social priorities into its activities. Through this document, Laboratoires Delbert commits to 10 principles for responsible purchasing.

10 COMMITMENTS TO RESPONSIBLE PURCHASING

01.

Ensure a responsible financial relationship with suppliers.

02.

Maintain a respectful relationship with all suppliers, favoring the development of collaborative relationships.

03.

Identify and manage reciprocal dependencies with suppliers.

04.

Involve signatory organizations in their industry.

05.

Appreciate all life-cycle costs and impacts.

06.

Integrate environmental and social responsibility issues.

07.

Ensure the territorial responsibility of its organization.

08.

The professionalism and ethics of the purchasing function.

09.

A Purchasing function responsible for overall management of supplier relations.

10.

A “supplier relations” mediator to smooth internal and external relations.

Article Le Monde: Delbert, saving essential medicines from dissapearing

Dec 2, 2022 | Unclassified

Article published on Lemonde.fr, December 2, 2022.

Since 2013, the pharmaceutical company has been fighting to breathe new life into essential old molecules threatened with disappearing from the therapeutic arsenal. With each new dossier that lands on its desk, the rule is always the same.

“We check that the medicine meets a clear medical need, then assess whether its development is technically feasible in France or Europe. If we’re 85% sure, we go ahead”, explains Thierry Hoffmann, Managing Director of Laboratoires Delbert.

READ MORE on lemonde.fr